Scott M Whitcup Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Scott M Whitcup.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Scott M Whitcup. Scott M Whitcup is Executive Vice President, R&D in ALLERGAN INC ($AGN) and Executive VP, R&D, CSO in ALLERGAN INC ($AGN) and Director in Menlo Therapeutics Inc. ($MNLO) and Director in Adverum Biotechnologies, Inc. ($ADVM) and Director in Nightstar Therapeutics plc ($NITE).
Latest Insider Trading Transactions of Scott M Whitcup
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ADVM, AGN, NITE, MNLO
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 14 2021 | ADVM | Adverum Biotechnol ... | Whitcup Scott M | Director | Option Exercise | A | 3.70 | 40,000 | 148,000 | 40,000 | |
| Jun 25 2020 | ADVM | Adverum Biotechnol ... | Whitcup Scott M | Director | Option Exercise | A | 25.64 | 30,000 | 769,200 | 30,000 | |
| Apr 20 2020 | ADVM | Adverum Biotechnol ... | Whitcup Scott M | Director | Option Exercise | A | 11.62 | 60,000 | 697,200 | 60,000 | |
| Jun 27 2019 | MNLO | Menlo Therapeutics ... | Whitcup Scott M | Director | Option Exercise | A | 6.02 | 22,500 | 135,450 | 134,099 | |
| Jun 07 2019 | NITE | Nightstar Therapeu ... | Whitcup Scott M | Director | Option Exercise | D | 13.57 | 21,000 | 284,970 | 0 | |
| Jun 07 2019 | NITE | Nightstar Therapeu ... | Whitcup Scott M | Director | Option Exercise | D | 12.27 | 18,200 | 223,314 | 0 | |
| Jun 07 2019 | NITE | Nightstar Therapeu ... | Whitcup Scott M | Director | Sell | D | 25.50 | 74,568 | 1,901,484 | 0 | 74.6 K to 0 (-100.00 %) |
| Jun 07 2019 | NITE | Nightstar Therapeu ... | Whitcup Scott M | Director | Option Exercise | D | 13.57 | 21,000 | 284,970 | 0 | |
| Jun 07 2019 | NITE | Nightstar Therapeu ... | Whitcup Scott M | Director | Option Exercise | D | 12.27 | 18,200 | 223,314 | 0 | |
| Jun 07 2019 | NITE | Nightstar Therapeu ... | Whitcup Scott M | Director | Sell | D | 25.50 | 74,568 | 1,901,484 | 0 | 74.6 K to 0 (-100.00 %) |
| Jan 29 2019 | NITE | Nightstar Therapeu ... | Whitcup Scott M | Director | Option Exercise | A | 13.57 | 21,000 | 284,970 | 21,000 | |
| Jan 29 2019 | NITE | Nightstar Therapeu ... | Whitcup Scott M | Director | Option Exercise | A | 13.57 | 21,000 | 284,970 | 21,000 | |
| Jan 15 2019 | MNLO | Menlo Therapeutics ... | Whitcup Scott M | Director | Option Exercise | M | 1.83 | 25,000 | 45,858 | 77,043 | |
| Mar 19 2015 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | D | 125.07 | 58,815 | 7,355,992 | 0 | |
| Mar 19 2015 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | D | 87.91 | 67,000 | 5,889,970 | 0 | |
| Mar 19 2015 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | D | 87.91 | 25,000 | 2,197,750 | 0 | |
| Mar 19 2015 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | D | 105.87 | 60,000 | 6,352,200 | 0 | |
| Mar 19 2015 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | D | 75.58 | 120,000 | 9,069,600 | 0 | |
| Mar 19 2015 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | D | 59.13 | 92,600 | 5,475,438 | 0 | |
| Mar 19 2015 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | D | 40.16 | 130,400 | 5,236,864 | 0 | |
| Mar 19 2015 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | D | 64.47 | 105,500 | 6,801,585 | 0 | |
| Mar 19 2015 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | D | 58.55 | 89,200 | 5,222,660 | 0 | |
| Mar 19 2015 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | D | 0.00 | 1,710 | 0 | 0 | 1.7 K to 0 (-100.00 %) |
| Mar 19 2015 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | D | 0.00 | 1,739 | 0 | 0 | 1.7 K to 0 (-100.00 %) |
| Mar 19 2015 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | D | 0.00 | 18,683 | 0 | 0 | 18.7 K to 0 (-100.00 %) |
| Mar 19 2015 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Grant | A | 0.00 | 11,274 | 0 | 18,683 | 7.4 K to 18.7 K (+152.17 %) |
| Mar 19 2015 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Gift | G | 0.00 | 9,766 | 0 | 7,409 | 17.2 K to 7.4 K (-56.86 %) |
| Feb 24 2015 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 0.00 | 212 | 0 | 0 | |
| Feb 24 2015 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | A | 0.00 | 212 | 0 | 212 | |
| Feb 24 2015 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Payment of Exercise | F | 234.00 | 80 | 18,720 | 17,175 | 17.3 K to 17.2 K (-0.46 %) |
| Feb 24 2015 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 0.00 | 212 | 0 | 17,255 | 17 K to 17.3 K (+1.24 %) |
| Feb 25 2014 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | A | 125.07 | 58,815 | 7,355,992 | 58,815 | |
| Feb 19 2014 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Payment of Exercise | F | 124.57 | 284 | 35,378 | 17,043 | 17.3 K to 17 K (-1.64 %) |
| Jan 15 2014 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 55.98 | 42,000 | 2,350,950 | 0 | |
| Jan 15 2014 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 118.80 | 21,000 | 2,494,800 | 17,327 | 38.3 K to 17.3 K (-54.79 %) |
| Jan 15 2014 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 116.80 | 21,000 | 2,452,800 | 38,327 | 59.3 K to 38.3 K (-35.40 %) |
| Jan 15 2014 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 55.98 | 42,000 | 2,350,950 | 59,327 | 17.3 K to 59.3 K (+242.40 %) |
| Jan 10 2014 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 55.98 | 42,000 | 2,350,950 | 42,000 | |
| Jan 10 2014 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 114.80 | 21,000 | 2,410,800 | 17,327 | 38.3 K to 17.3 K (-54.79 %) |
| Jan 10 2014 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 112.80 | 21,000 | 2,368,800 | 38,327 | 59.3 K to 38.3 K (-35.40 %) |
| Jan 10 2014 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 55.98 | 42,000 | 2,350,950 | 59,327 | 17.3 K to 59.3 K (+242.40 %) |
| Jan 06 2014 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 36.15 | 16,500 | 596,475 | 24,200 | |
| Jan 06 2014 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 36.15 | 16,500 | 596,475 | 40,700 | |
| Jan 06 2014 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 109.80 | 16,500 | 1,811,700 | 17,327 | 33.8 K to 17.3 K (-48.78 %) |
| Jan 06 2014 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 0.00 | 16,500 | 0 | 33,827 | 17.3 K to 33.8 K (+95.23 %) |
| Jan 06 2014 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 107.80 | 16,500 | 1,778,700 | 17,327 | 33.8 K to 17.3 K (-48.78 %) |
| Jan 06 2014 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 0.00 | 16,500 | 0 | 33,827 | 17.3 K to 33.8 K (+95.23 %) |
| Dec 20 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 36.15 | 16,500 | 596,475 | 24,200 | |
| Dec 20 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 36.15 | 16,500 | 596,475 | 40,700 | |
| Dec 20 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 109.80 | 16,500 | 1,811,700 | 17,327 | 33.8 K to 17.3 K (-48.78 %) |
| Dec 20 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 36.15 | 16,500 | 596,475 | 33,827 | 17.3 K to 33.8 K (+95.23 %) |
| Dec 20 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 107.80 | 16,500 | 1,778,700 | 17,327 | 33.8 K to 17.3 K (-48.78 %) |
| Dec 20 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 36.15 | 16,500 | 596,475 | 33,827 | 17.3 K to 33.8 K (+95.23 %) |
| Apr 15 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 36.15 | 12,005 | 433,981 | 57,200 | |
| Apr 15 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 115.00 | 12,005 | 1,380,575 | 17,327 | 29.3 K to 17.3 K (-40.93 %) |
| Apr 15 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 36.15 | 12,005 | 433,981 | 29,332 | 17.3 K to 29.3 K (+69.28 %) |
| Apr 05 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 36.15 | 13,195 | 476,999 | 69,205 | |
| Apr 05 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 115.00 | 13,195 | 1,517,425 | 17,327 | 30.5 K to 17.3 K (-43.23 %) |
| Apr 05 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 36.15 | 13,195 | 476,999 | 30,522 | 17.3 K to 30.5 K (+76.15 %) |
| Apr 02 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 41.24 | 8,000 | 329,920 | 0 | |
| Apr 02 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 111.70 | 8,000 | 893,622 | 17,327 | 25.3 K to 17.3 K (-31.59 %) |
| Apr 02 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 41.24 | 8,000 | 329,920 | 25,327 | 17.3 K to 25.3 K (+46.17 %) |
| Mar 27 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 36.15 | 11,484 | 415,147 | 82,400 | |
| Mar 27 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 112.00 | 11,484 | 1,286,208 | 17,327 | 28.8 K to 17.3 K (-39.86 %) |
| Mar 27 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 36.15 | 11,484 | 415,147 | 28,811 | 17.3 K to 28.8 K (+66.28 %) |
| Mar 25 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 36.15 | 4,925 | 178,039 | 93,884 | |
| Mar 25 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 36.15 | 1,191 | 43,055 | 98,809 | |
| Mar 25 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 112.00 | 4,925 | 551,600 | 17,327 | 22.3 K to 17.3 K (-22.13 %) |
| Mar 25 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 36.15 | 4,925 | 178,039 | 22,252 | 17.3 K to 22.3 K (+28.42 %) |
| Mar 25 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 112.00 | 1,191 | 133,392 | 17,327 | 18.5 K to 17.3 K (-6.43 %) |
| Mar 25 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 36.15 | 1,191 | 43,055 | 18,518 | 17.3 K to 18.5 K (+6.87 %) |
| Feb 22 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | A | 105.87 | 60,000 | 6,352,200 | 60,000 | |
| Feb 22 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Payment of Exercise | F | 108.08 | 5,218 | 563,961 | 17,327 | 22.5 K to 17.3 K (-23.14 %) |
| Feb 20 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Payment of Exercise | F | 108.02 | 434 | 46,881 | 22,545 | 23 K to 22.5 K (-1.89 %) |
| Jan 07 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 41.24 | 24,000 | 989,760 | 8,000 | |
| Jan 07 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 96.80 | 24,000 | 2,323,200 | 22,979 | 47 K to 23 K (-51.09 %) |
| Jan 07 2013 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 41.24 | 24,000 | 989,760 | 46,979 | 23 K to 47 K (+104.44 %) |
| Dec 11 2012 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 30.13 | 6,800 | 204,850 | 0 | |
| Dec 11 2012 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 91.23 | 6,800 | 620,391 | 22,979 | 29.8 K to 23 K (-22.83 %) |
| Dec 11 2012 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 30.13 | 6,800 | 204,850 | 29,779 | 23 K to 29.8 K (+29.59 %) |
| Oct 18 2012 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 30.13 | 5,000 | 150,625 | 6,800 | |
| Oct 18 2012 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 94.70 | 5,000 | 473,500 | 22,979 | 28 K to 23 K (-17.87 %) |
| Oct 18 2012 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 30.13 | 5,000 | 150,625 | 27,979 | 23 K to 28 K (+21.76 %) |
| Oct 02 2012 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 30.13 | 6,000 | 180,750 | 11,800 | |
| Oct 02 2012 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 92.70 | 6,000 | 556,200 | 22,979 | 29 K to 23 K (-20.70 %) |
| Oct 02 2012 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 30.13 | 6,000 | 180,750 | 28,979 | 23 K to 29 K (+26.11 %) |
| May 31 2012 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 30.13 | 1,500 | 45,188 | 17,800 | |
| May 31 2012 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 90.71 | 1,500 | 136,062 | 22,979 | 24.5 K to 23 K (-6.13 %) |
| May 31 2012 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 30.13 | 1,500 | 45,188 | 24,479 | 23 K to 24.5 K (+6.53 %) |
| May 18 2012 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 30.13 | 1,500 | 45,188 | 19,300 | |
| May 18 2012 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 92.00 | 1,500 | 138,000 | 22,979 | 24.5 K to 23 K (-6.13 %) |
| May 18 2012 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 30.13 | 1,500 | 45,188 | 24,479 | 23 K to 24.5 K (+6.53 %) |
| Feb 24 2012 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Payment of Exercise | F | 87.27 | 45 | 3,927 | 22,979 | 23 K to 23 K (-0.20 %) |
| Feb 22 2012 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | A | 87.91 | 25,000 | 2,197,750 | 25,000 | |
| Feb 22 2012 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | A | 87.91 | 67,000 | 5,889,970 | 67,000 | |
| Feb 22 2012 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Grant | A | 0.00 | 544 | 0 | 23,024 | 22.5 K to 23 K (+2.42 %) |
| Feb 16 2012 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Payment of Exercise | F | 88.11 | 1,470 | 129,514 | 22,480 | 24 K to 22.5 K (-6.14 %) |
| May 19 2011 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 28.92 | 5,500 | 159,060 | 0 | |
| May 19 2011 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 83.89 | 5,500 | 461,400 | 23,950 | 29.5 K to 24 K (-18.68 %) |
| May 19 2011 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 28.92 | 5,500 | 159,060 | 29,450 | 24 K to 29.5 K (+22.96 %) |
| May 12 2011 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 80.85 | 608 | 49,156 | 23,950 | 24.6 K to 24 K (-2.48 %) |
| May 05 2011 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 28.92 | 2,000 | 57,840 | 5,500 | |
| May 05 2011 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 80.80 | 2,000 | 161,600 | 24,558 | 26.6 K to 24.6 K (-7.53 %) |
| May 05 2011 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 28.92 | 2,000 | 57,840 | 26,558 | 24.6 K to 26.6 K (+8.14 %) |
| Feb 22 2011 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | A | 75.58 | 120,000 | 9,069,600 | 120,000 | |
| Feb 22 2011 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Grant | A | 0.00 | 830 | 0 | 24,558 | 23.7 K to 24.6 K (+3.50 %) |
| Feb 18 2011 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 75.72 | 4,000 | 302,891 | 23,728 | 27.7 K to 23.7 K (-14.43 %) |
| Dec 15 2010 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 40.09 | 15,020 | 602,132 | 0 | |
| Dec 15 2010 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 69.48 | 15,020 | 1,043,608 | 27,728 | 42.7 K to 27.7 K (-35.14 %) |
| Dec 15 2010 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 40.09 | 15,020 | 602,132 | 42,748 | 27.7 K to 42.7 K (+54.17 %) |
| Dec 02 2010 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 40.09 | 7,400 | 296,656 | 15,020 | |
| Dec 02 2010 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 67.14 | 7,400 | 496,847 | 27,728 | 35.1 K to 27.7 K (-21.07 %) |
| Dec 02 2010 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 40.09 | 7,400 | 296,656 | 35,128 | 27.7 K to 35.1 K (+26.69 %) |
| Apr 01 2010 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 32.39 | 7,212 | 233,623 | 0 | |
| Apr 01 2010 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 65.20 | 7,212 | 470,248 | 27,728 | 34.9 K to 27.7 K (-20.64 %) |
| Apr 01 2010 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 32.39 | 7,212 | 233,623 | 34,940 | 27.7 K to 34.9 K (+26.01 %) |
| Feb 24 2010 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | A | 59.13 | 92,600 | 5,475,438 | 92,600 | |
| Feb 24 2010 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Grant | A | 0.00 | 120 | 0 | 27,728 | 27.6 K to 27.7 K (+0.43 %) |
| Feb 17 2010 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Payment of Exercise | F | 58.97 | 756 | 44,578 | 27,608 | 28.4 K to 27.6 K (-2.67 %) |
| Dec 23 2009 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 32.39 | 8,000 | 259,150 | 7,212 | |
| Dec 23 2009 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 62.20 | 8,000 | 497,600 | 28,364 | 36.4 K to 28.4 K (-22.00 %) |
| Dec 23 2009 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 32.39 | 8,000 | 259,150 | 36,364 | 28.4 K to 36.4 K (+28.20 %) |
| Sep 17 2009 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 32.39 | 5,000 | 161,969 | 15,212 | |
| Sep 17 2009 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 58.20 | 5,000 | 291,000 | 28,364 | 33.4 K to 28.4 K (-14.99 %) |
| Sep 17 2009 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 32.39 | 5,000 | 161,969 | 33,364 | 28.4 K to 33.4 K (+17.63 %) |
| Jul 31 2009 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Option Exercise | M | 32.39 | 2,000 | 64,787 | 20,212 | |
| Jul 31 2009 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Sell | S | 53.35 | 2,000 | 106,700 | 28,363 | 30.4 K to 28.4 K (-6.59 %) |
| Jul 31 2009 | AGN | ALLERGAN INC | Whitcup Scott M | Executive VP, R&D, ... | Buy | M | 32.39 | 2,000 | 64,787 | 30,363 | 28.4 K to 30.4 K (+7.05 %) |
| Feb 24 2009 | AGN | ALLERGAN INC | Whitcup Scott M | Executive Vice Pres ... | Option Exercise | A | 40.16 | 130,400 | 5,236,864 | 130,400 | |
| Feb 24 2009 | AGN | ALLERGAN INC | Whitcup Scott M | Executive Vice Pres ... | Grant | A | 0.00 | 10,000 | 0 | 28,363 | 18.4 K to 28.4 K (+54.46 %) |
| Feb 04 2009 | AGN | ALLERGAN INC | Whitcup Scott M | Executive Vice Pres ... | Sell | D | 38.37 | 584 | 22,405 | 18,363 | 18.9 K to 18.4 K (-3.08 %) |
| Feb 19 2008 | AGN | ALLERGAN INC | Whitcup Scott M | Executive Vice Pres ... | Option Exercise | A | 64.47 | 105,500 | 6,801,585 | 105,500 | |
| Feb 19 2008 | AGN | ALLERGAN INC | Whitcup Scott M | Executive Vice Pres ... | Grant | A | 0.00 | 4,000 | 0 | 18,947 | 14.9 K to 18.9 K (+26.76 %) |
| Feb 19 2008 | AGN | ALLERGAN INC | Whitcup Scott M | Executive Vice Pres ... | Grant | A | 0.00 | 1,997 | 0 | 14,947 | 13 K to 14.9 K (+15.42 %) |
| Feb 08 2008 | AGN | ALLERGAN INC | Whitcup Scott M | Executive Vice Pres ... | Payment of Exercise | F | 66.66 | 728 | 48,525 | 12,950 | 13.7 K to 13 K (-5.32 %) |
| Feb 01 2008 | AGN | ALLERGAN INC | Whitcup Scott M | Executive Vice Pres ... | Payment of Exercise | F | 64.00 | 2,168 | 138,752 | 13,678 | 15.8 K to 13.7 K (-13.68 %) |
| Jun 04 2007 | AGN | ALLERGAN INC | Whitcup Scott M | Executive Vice Pres ... | Option Exercise | M | 106.26 | 6,966 | 740,207 | 0 | |
| Jun 04 2007 | AGN | ALLERGAN INC | Whitcup Scott M | Executive Vice Pres ... | Option Exercise | M | 106.26 | 200 | 21,252 | 6,966 | |
| Jun 04 2007 | AGN | ALLERGAN INC | Whitcup Scott M | Executive Vice Pres ... | Sell | S | 123.58 | 6,966 | 860,858 | 7,925 | 14.9 K to 7.9 K (-46.78 %) |
| Jun 04 2007 | AGN | ALLERGAN INC | Whitcup Scott M | Executive Vice Pres ... | Buy | M | 106.26 | 6,966 | 740,207 | 14,891 | 7.9 K to 14.9 K (+87.90 %) |
| Jun 04 2007 | AGN | ALLERGAN INC | Whitcup Scott M | Executive Vice Pres ... | Sell | S | 125.00 | 200 | 25,000 | 7,925 | 8.1 K to 7.9 K (-2.46 %) |
| Jun 04 2007 | AGN | ALLERGAN INC | Whitcup Scott M | Executive Vice Pres ... | Buy | M | 106.26 | 200 | 21,252 | 8,125 | 7.9 K to 8.1 K (+2.52 %) |
| May 29 2007 | AGN | ALLERGAN INC | Whitcup Scott M | Executive Vice Pres ... | Option Exercise | M | 106.26 | 100 | 10,626 | 7,166 | |
| May 29 2007 | AGN | ALLERGAN INC | Whitcup Scott M | Executive Vice Pres ... | Sell | S | 125.00 | 100 | 12,500 | 7,925 | 8 K to 7.9 K (-1.25 %) |
| May 29 2007 | AGN | ALLERGAN INC | Whitcup Scott M | Executive Vice Pres ... | Buy | M | 106.26 | 100 | 10,626 | 8,025 | 7.9 K to 8 K (+1.26 %) |
| Feb 06 2007 | AGN | ALLERGAN INC | Whitcup Scott M | Executive Vice Pres ... | Option Exercise | A | 117.10 | 44,600 | 5,222,660 | 44,600 | |
| Feb 06 2007 | AGN | ALLERGAN INC | Whitcup Scott M | Executive Vice Pres ... | Grant | A | 0.00 | 682 | 0 | 7,924 | 7.2 K to 7.9 K (+9.42 %) |
| Feb 02 2007 | AGN | ALLERGAN INC | Whitcup Scott M | Executive Vice Pres ... | Payment of Exercise | F | 115.80 | 1,799 | 208,324 | 7,242 | 9 K to 7.2 K (-19.90 %) |
| Nov 22 2006 | AGN | ALLERGAN INC | Whitcup Scott M | Executive Vice Pres ... | Option Exercise | M | 88.55 | 7,266 | 643,404 | 0 | |
| Nov 22 2006 | AGN | ALLERGAN INC | Whitcup Scott M | Executive Vice Pres ... | Sell | S | 120.00 | 7,266 | 871,920 | 9,040 | 16.3 K to 9 K (-44.56 %) |